Avondale rated Mkt Outperform Hanger Orthopedic Group, Inc. (NYSE: HGR) on 09/25/2008, when the stock price was $17.50. Since then, Hanger Orthopedic Group, Inc. has gained 77.89% as of 05/24/2013's recent price of $31.13.
If you would have followed this Avondale's recommendation on HGR, you would have gained 77.88% of your investment in 1702 days.

Hanger Orthopedic Group Inc. owns and operates orthotic and prosthetic (O&P) patient-care centers in the United States. Hanger Orthopedic Group, through its wholly owned subsidiary, Southern Prosthetic Supply, Inc. (SPS), distributes branded and private label O&P devices and components in the United States, all of which are manufactured by third parties. The Company also creates new products, through its wholly owned subsidiary, Innovative Neurotronics, Inc. (IN Inc.) for patients who have had a loss of mobility due to strokes, multiple sclerosis or other similar conditions. In May 2009, the Company acquired Northwest Prosthetic & Orthotic Clinic and Inline Orthotic and Prosthetic Systems. In October 2009, Hanger Orthopedic Group Inc. acquired Creative Orthotics & Prosthetics, Inc., Custom Orthopedics of Wyoming and certain orthotics and prosthetics assets from the Hospital of the University of Pennsylvania.

Avondale’s research analysts are charged with producing high quality, independent, value-added, and timely investment analysis / advice. The firm’s strategy is to deemphasize maintenance research, and instead direct the overwhelming majority of our efforts on developing well-constructed, actionable recommendations, in part by leveraging proprietary networks of industry contacts. Avondale’s growing research department now totals 25 professionals. Senior analysts average 14 years of industry experience and are routinely recognized by a variety of nationally known rating entities. In the last two years, Avondale Analysts were named to the Wall Street Journal’s Best on the Street poll as well as Forbes.com’s Top Analyst Rankings.

Marked as spam